Global Human Plasma Fractionation Product Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Plasma Fractionation Product Market Research Report 2024
Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Blood Plasma Fractionation.
According to Mr Accuracy reports’s new survey, global Human Plasma Fractionation Product market is projected to reach US$ 50750 million in 2029, increasing from US$ 30330 million in 2022, with the CAGR of 7.6% during the period of 2024 to 2029.
The Human Plasma Fractionation Product Market is driven by the increasing demand for plasma-derived therapies and the rising prevalence of various diseases. These products, including clotting factors and immunoglobulins, are crucial for treating rare and life-threatening conditions. However, a significant challenge is the need for a stable supply of plasma donations and the complex fractionation processes required to manufacture these products. Ensuring the safety and quality of plasma-derived therapies through strict regulatory compliance is another challenge for manufacturers. Additionally, market competition and pricing pressures pose challenges, necessitating a balance between affordability and sustaining the supply chain to meet the healthcare demands while maintaining the highest standards of patient care.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Plasma Fractionation Product market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Segment by Type
Immune Globulin
Coagulation Factor
Albumin
Other
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Human Plasma Fractionation Product report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Human Plasma Fractionation Product market is projected to reach US$ 50750 million in 2029, increasing from US$ 30330 million in 2022, with the CAGR of 7.6% during the period of 2024 to 2029.
The Human Plasma Fractionation Product Market is driven by the increasing demand for plasma-derived therapies and the rising prevalence of various diseases. These products, including clotting factors and immunoglobulins, are crucial for treating rare and life-threatening conditions. However, a significant challenge is the need for a stable supply of plasma donations and the complex fractionation processes required to manufacture these products. Ensuring the safety and quality of plasma-derived therapies through strict regulatory compliance is another challenge for manufacturers. Additionally, market competition and pricing pressures pose challenges, necessitating a balance between affordability and sustaining the supply chain to meet the healthcare demands while maintaining the highest standards of patient care.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Plasma Fractionation Product market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Segment by Type
Immune Globulin
Coagulation Factor
Albumin
Other
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Human Plasma Fractionation Product report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source